Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

被引：4
作者：
Chow, Laura Quan Man
Mehra, Ranee
Haddad, Robert I.
Mahipal, Amit
Weiss, Jared
Berger, Raanan
Eder, Joseph Paul
Burtness, Barbara
Tahara, Makoto
Keam, Bhumsuk
Le, Dung T.
Muro, Kei
Geva, Ravit
Chung, Hyun Cheol
Lin, Chia-Chi
Ayers, Mark
Aurora-Garg, Deepti
Lunceford, Jared K.
Cheng, Jonathan D.
Seiwert, Tanguy Y.
机构：
[1] Seattle Canc Care Alliance, Seattle, WA USA
[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[6] Sheba Med Ctr, Tel Hashomer, Israel
[7] Yale Canc Ctr, New Haven, CT USA
[8] Natl Canc Ctr Hosp East, Chiba, Japan
[9] Seoul Natl Univ Hosp, Seoul, South Korea
[10] Johns Hopkins Univ, Baltimore, MD USA
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Sourasky Med Ctr, Tel Aviv, Israel
[13] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[14] Natl Taiwan Univ Hosp, Taipei, Taiwan
[15] Merck & Co Inc, Kenilworth, NJ USA
[16] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6010
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort
    Lynggaard, Charlotte Duch
    Therkildsen, Marianne Hamilton
    Kristensen, Claus Andrup
    Specht, Lena
    ACTA ONCOLOGICA, 2015, 54 (07) : 1071 - U151
  • [22] Pembrolizumab for cisplatin-failure recurrent/metastatic head and neck squamous cell carcinoma
    Chen, W-C.
    Chang, P. M-H.
    Lee, Y-T.
    Lu, W-B.
    Yang, M-H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study
    Harrington, Kevin
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra
    Licitra, Lisa
    Rischin, Danny
    Zhu, Ying
    Okpara, Chinyere E.
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal
    Tahara, Makoto
    ORAL ONCOLOGY, 2021, 118
  • [24] Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy
    Harrington, K.
    Cohen, E.
    Siu, L.
    Rischin, D.
    Licitra, L.
    Vermorken, J.
    Le, Q. T.
    Tahara, M.
    Machiels, J. P.
    Hawk, N.
    Ge, J.
    Bidadi, B.
    Swaby, R.
    Burtness, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E43 - E44
  • [25] Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040
    Soulieres, D.
    Harrington, K. J.
    Le Tourneau, C.
    Silva, J. D.
    Licitra, L. F.
    Ahn, M-J.
    Soria, A.
    Machiels, J-P.
    Mach, N.
    Mehra, R.
    Burtness, B.
    Lin, J.
    Lerman, N.
    Gumuscu, B.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S843 - S843
  • [26] Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra E. W.
    Harrington, Kevin Joseph
    Licitra, Lisa F.
    Rischin, Danny
    Zhu, Ying
    Lee, Chooi Peng
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal H.
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Circulating tumor DNA kinetics in recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) patients
    Taylor, K.
    Zou, J.
    Burgener, J.
    Zhao, E.
    Torti, D.
    Oliva, M.
    Spreafico, A.
    Hansen, A. R.
    Jang, R.
    McDade, S. S.
    Coyle, V. M.
    Lawler, M.
    Elimova, E.
    Bratman, S. V.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S796 - S797
  • [28] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [29] LncRNAs as prognostic biomarkers in head and neck squamous cell carcinoma (HNSCC)
    Chaudhary, Ritu
    Wang, Xuefeng
    Cao, Biwei
    Gimbrone, Nicholas T.
    Slebos, Robbert J. C.
    Chung, Christine H.
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors
    Kitahara, H.
    Kobayashi, Y.
    Hirai, M.
    Kawashiri, S.
    Nakamura, H.
    ANNALS OF ONCOLOGY, 2018, 29
12345